Clinical Trials Browser

selinexor × Gynecologic × Clear all

NCT07215832 2026-03-02

KEAP

GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT04811196 2025-05-29

A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

Phase 1 Completed

GynecologicSarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Endometrial Stromal, Neurofibrosarcoma

NCT03555422 2025-01-20

ENGOT-EN5

Phase 3 Active not recruiting

Genital Diseases, Neoplasms, Neoplasms by Site, Uterine Diseases, Uterine Neoplasms, Endometrial Neoplasms

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms, Recurrence

NCT02025985 2023-01-26

SIGN

Phase 2 Completed

116 enrolled 21 charts

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02269293 2021-04-23

Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

Phase 1 Completed

Ovarian Neoplasms, Endometrial Neoplasms